Australia's most trusted
source of pharma news
Friday, 24 April 2026
Posted 24 April 2026 AM
Supply resilience may need to be factored into PBS listing decisions according to an industry expert, as geopolitical tensions expose the fragility of global pharma supply chains.
Former GSK executive, government advisor and now CEO of the Thoracic Society of ANZ, Vincent So, said while the current supply chain works well under 'normal conditions', it is optimised for efficiency and cost rather than resilience.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.